基于移动靶区剂量模型优化肺VMAT SBRT的PTV边界以纳入呼吸运动不确定性
本研究回顾性分析31例非小细胞肺癌患者的4D CT和Synchrony追踪日志数据,提出移动靶区剂量(MTD)模型计算肺VMAT SBRT的PTV边界,并与时空(ST)等模型比较。MTD模型所得边界最小,上叶S-I方向3.10 mm,下叶S-I方向5.28 mm,且边界随治疗时间延长而增大。
要点
- MTD模型计算的PTV边界小于ST等模型,上叶S-I方向为3.10 mm,下叶为5.28 mm。
- 下叶肿瘤S-I方向边界(5.28 mm)明显大于上叶(3.10 mm)。
- 治疗时间延长时边界通常增大,主要与呼吸基线漂移和短期误差波动有关。
核心结论
- 将剂量学因素纳入PTV定义可兼顾GTV累积剂量覆盖与减少正常组织暴露,MTD模型计算的边界小于单纯时空分析模型。
研究设计与样本
- 回顾性分析31例非小细胞肺癌患者(上叶15例、下叶16例),均行4D CT模拟,并利用Synchrony呼吸追踪系统日志文件提取三维坐标表征肿瘤运动。
主要发现
- MTD模型计算的上叶边界为S-I 3.10 mm、A-P 0.98 mm、L-R 0.41 mm,下叶为S-I 5.28 mm、A-P 1.00 mm、L-R 0.80 mm。
- 与MTD模型相比,ST模型上叶边界增大S-I 1.47 mm、L-R 0.84 mm、A-P 1.31 mm,下叶增大S-I 2.00 mm、L-R 1.12 mm、A-P 1.49 mm。
- 不同方法所得边界在病理位置和方向上模式一致,但幅度差异显著,MTD模型结果最小。
关键数值与推荐
- MTD模型计算边界以确保GTV在治疗中接受至少95%的处方剂量,并按解剖方向和肿瘤位置分层。
临床怎么用
- 对于自由呼吸下肺SBRT,可考虑用MTD模型替代保守的时空模型边界,以在保证GTV累积剂量覆盖的同时减少正常组织受量。
局限性
- 本研究为回顾性分析,样本量31例,未来计算需通过方差合成纳入设备/治疗师特异性不确定性以优化边界公式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adding a Planning Target Volume (PTV) margin remains a straightforward and effective strategy to ensure adequate target coverage under various uncertainties. Appropriately reduced margins can minimize treatment-related toxicity without compromising tumor control. However, respiratory motion introduces complex interactions with Internal Target Volume (ITV) management, making conventional PTV recipes less reliable. This study aims to refine the definition of PTV margin for lung stereotactic body radiotherapy (SBRT) using a moving target dose (MTD) model to account for respiratory motion uncertainty under free breathing, and to compare it with alternative margin calculation methods. METHODS: Data from 31 patients with non-small-cell lung cancer (15 in the upper lobe, 16 in the lower lobe) were retrospectively analyzed. All patients underwent Four-Dimensional (4D) CT simulation and tumor motion tracking during treatment, represented by three-dimensional coordinates extracted from log files generated by Synchrony Respiratory Tracking System, which were used to characterize displacement along the superior-inferior (S–I), anterior-posterior (A–P), and left-right (L–R) axis. The MTD model is proposed to assess the accumulative dose of the moving target considering both motion and dose fall-off outside of the PTV from VMAT treatment, then margins were calculated to ensure Gross Tumor Volume (GTV) receives a minimum of 95% of the prescribed dose during treatment, stratified both by anatomical direction and tumor location. RESULTS: While the results of different methods exhibit a consistent pattern across pathological locations and different directions, they show significant discrepancies in magnitude. The smallest result is derived from the MTD model, whereas the spatial-temporal (ST) and adjusted van Herk models yield slightly larger result than the others. As calculated using the MTD model, for the upper-lobe group, the margins were 3.10 mm (S–I), 0.98 mm (A–P), and 0.41 mm (L–R), whereas for the lower-lobe group, the corresponding margins were 5.28 mm (S–I), 1.00 mm (A–P), and 0.80 mm (L–R), respectively. Compared with MTD model, upper-lobe margins from ST model was larger by 1.47 mm (S–I), 0.84 mm (L–R), and 1.31 mm (A–P), whereas lower-lobe margin increased by 2.00 mm (S–I), 1.12 mm (L–R), and 1.49 mm (A–P). Notably, the margins would generally increase with prolonged treatment time, majorly caused by respiratory baseline drift effects and short-term error fluctuations. CONCLUSION: Our study provided a method of incorporating dosimetric factors into PTV definition for lung SBRT to account for respiratory motion-induced uncertainties. Margins derived solely from spatial-temporal analysis are relatively conservative, whereas the MTD model provides a margin definition relevant to the accumulated dose by the target, potentially balancing GTV cumulative dose coverage with reduced normal tissue exposure. For clinical robustness, future calculation should incorporate device/therapist-specific uncertainties via variance summation to refine margin recipe. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Fu Y, Xu Z, Xue Y, et al. Refining the PTV margin determination for VMAT SBRT lung treatment through moving target dose model to account for respiratory motion uncertainty. Radiat Oncol. 2026. PMID: 41654964. doi:10.1186/s13014-026-02795-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。